After the global panic created by COVID-19, the monkeypox (Mpox) virus emerged as a new challenge for the world population. As of 19 January 2023, a total of 84,733 cases across 110 countries/territories including 80 deaths has been reported. The virus has been transmitted to nonendemic countries in a short span of 6 months warranting WHO to declare Mpox, a Public Health Emergency of International Concern on 23 July 2022. As the Mpox virus is crossing geographical boundaries without established transmission patterns, there is an urgent need for new scientific strategies from global researchers to contain it before turning into the next pandemic. The control of Mpox outbreaks primarily relies on various public health measures such as proper surveillance, contact tracing, rapid diagnosis, isolation and care of patients, and vaccination. At present, there are three vaccines viz. ACAM2000, MVABN, and LC16 are in consideration and have been approved in several jurisdictions for ongoing Mpox outbreak. Prioritization of individuals along with the production of specific Mpox vaccine is need of the hour to meet out the global demand of Mpox vaccination.
27 September 2015 in Indian Journal of Animal Research
The present paper reports a case of benign melanocytoma in an 8- years old non-descript cow, which are reported less commonly in India. The tumour was located on ventral aspect of neck and was surgically removed with successful recovery. Histopathological expression of the tumour suggests its benign nature which is also confirmed by its non-recurrence after 2 years of its surgical removal.
Decades have been witnessing clusters of zoonotic diseases. Human beings at the peak of evolution should not be empowered to alter the environmental homeostasis. Primitive organisms are more rooted to mutate and adapt as per the need or turmoil. Once humans come in the vicinity of these organisms normally residing in their native niche, nature has to pay the cost. Disease outbreaks mostly caused due to unnecessary anthropogenic activities. The threat is that the repercussions are taken for granted or hided wreaking havoc in developing and developed economies leading to an outbreak, an epidemic or a pandemic. The worst influenza outbreak in the world was the 1918 flu that killed nearly 50 million people around the world and modern strains still have an annual death toll in thousands, so the flu is no trifling matter even in a world still facing SARS-CoV-2. Recently, researchers estimated the expected yearly cost of pandemic influenza at roughly $500 billion (0.6 percent of global income), including both lost income and the intrinsic cost of elevated mortality.1
Lumpy skin disease (LSD) is a transboundary viral disease caused by lumpy skin disease virus (LSDV), belonging to the Capripoxvirus genus and Poxviridae family. This study reports on the molecular detection, seroprevalence and biochemical analysis of samples from cattle infected with LSDV in Madhya Pradesh (MP) and Telangana. A total of 189 samples (116 blood, 26 tissue, 47 nasal swabs) were collected from MP during 2022–2023. Molecular detection was performed using conventional PCR targeting the P32 and fusion genes, while seroprevalence was assessed using an indirect ELISA kit on 184 serum samples collected from MP and Telangana between 2022 and 2024. Tissue samples showed a higher positivity rate (69.23%) for the P32 gene, while nasal swabs had a 6.38% positivity rate. The fusion gene was detected in 77.77% of tissue and 66.66% of nasal swab samples. The seroprevalence study revealed that 19.56% of serum samples were positive, with a higher prevalence of 86.11% in MP. Biochemical analysis indicated elevated levels of SGPT, SGOT, BUN, creatinine, albumin, globulin and the A/G ratio in LSDV-infected cattle, though these differences were not statistically significant. The study emphasizes that blood samples are not ideal for LSDV detection and the timing of serum sample collection plays a critical role in seroprevalence studies.